商业房地产基金,快速诊断感染的生物技术,六个投资机会!博客
investment $500. InSitu 生物制品 - Closing soon. Emerging Biotech company focusing ... non-opiate, non-addictive painkiller. The InSitu 生物制品 offer is closing soon. Minimum ...
investment $500. InSitu 生物制品 - Closing soon. Emerging Biotech company focusing ... non-opiate, non-addictive painkiller. The InSitu 生物制品 offer is closing soon. Minimum ...
a maximum of $30 mill. InSitu 生物制品 原位 生物制品 is an emerging ...
of an annual $90 billion market opportunity. InSitu 生物制品' focus ... of shares is nearly sold out. InSitu 生物制品 is accepting a limited amount of investments at $6.90 per share. *Due to the demand for InSitu 生物制品' 库存, ...
和 生物学, the official journal of WMIS. Dr. Moore holds a PhD in Bioorganic ... 生物学, genetics, and tumor 生物学 and therapy. She developed the core ... (small-molecule/生物制剂/nucleic acid-based) and Biomarker Development; (Companion) Diagnostics (IVD, ...
in InSitu 生物制品' AnestaGel™, a patented non-opioid pain relief drug ... will then receive a private invitation to invest from InSitu 生物制品 ...
and improvements Check out Golf Suites 1 InSitu 生物制品 - Anyone can invest ...
unit price. Insitu 生物制品 Completed Their Raise to fund AnestaGel™, ...
in InSitu 生物制品AnestaGel™,一种基于非阿片类止痛药的...
investment $500. InSitu 生物制品 - Max raise $10mill. Anyone can invest ...
可转换债券每年支付10%。 最低投资额$ 10,000